A Phase 2 interventional study of Daratumumab 16 mg/kg (Part 1) and Daratumumab 8 mg/kg (Part 1) in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 34th largest by enrollment, is the only one that started in 2013, is one of 73 in phase 2, and was the 2nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 51st largest by enrollment of the 100 interventional ones that give a count, is one of 2 that started in 2013, is one of 32 in phase 2, and was the 51st registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD.
This is an open-label (identity of assigned study drug will be known) study of daratumumab for the treatment of participants with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an IMiD or whose disease is double refractory to both a PI and an IMiD. Up to approximately 150 participants are to be enrolled. The study includes screening, treatment, and follow-up phases. Participants will receive daratumumab by intravenous infusion (28-day cycles) until disease progression, unacceptable toxicity, or other protocol-defined reasons. For all study drug administrations, participants will receive pre- and post-infusion medications for the prevention of infusion related reactions. Follow-up will continue until death, loss to follow up, consent withdrawal for study participation, or study end, whichever occurs first. The study will consist of 2 sequential parts (Part 1 and Part 2). The purpose of Part 1 is to select a dose and schedule for Part 2 of the study. Assessment of tumor response and disease progression will be conducted according to IMWG response criteria. Serial pharmacokinetic blood samples and a pharmacogenomic blood sample will be collected. Safety will be monitored throughout the study. At the end of the study, participants who are benefiting from treatment with daratumumab will have the option to continue treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
Drug: Daratumumab 16 mg/kg (Part 1) · Drug: Daratumumab 8 mg/kg (Part 1) · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine
Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Daratumumab (Part 2)
Drug page: Daratumumab
Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
Drug page: Daratumumab
Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
Percentage of Participants With Overall Response
Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.
Time frame: Up to 14.4 Months
Duration of Response
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in IMWG criteria. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component (the absolute increase must be \>=0.5 g/dL) and/or; urine M-component (the absolute increase must be \>=200 mg/24 hours) and/or; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 milligram per deciliter (mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter \[mmol/L\]) that can be attributed solely to the plasma cell proliferative disorder.
Time frame: Up to 14.4 Months
Overall Survival
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.
Time frame: Approximately up to 3 years
Percentage of Participants With Clinical Benefit
Clinical benefit rate defined as percentage of participants who achieved minimal response (MR) or better. MR: \>=25% but \<= 49% reduction of serum M-protein and reduction in urine M-protein by 50%-89%. If present at baseline 25% to 49% reduction in size of soft tissue plasmacytomas.
Time frame: Up to 14.4 Months
Time to Response
Time to response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better).
Time frame: Up to 14.4 Months
Progression Free Survival
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.
Time frame: Up to 14.4 Months
Time to Disease Progression
Time to progression was defined as the number of days from the date of first dose of daratumumab to the date of first record of disease progression.
Time frame: Up to 14.4 Months
| Milestone | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Started | 18 | 106 |
| Completed | 0 | 0 |
| Not completed | 18 | 106 |
| Withdrew: Death | 15 | 69 |
| Withdrew: Lost to follow-up | 0 | 8 |
| Withdrew: Study terminated by sponsor | 1 | 22 |
| Withdrew: Withdrawal by subject | 2 | 7 |
Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.
| percentage of participants | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Percentage of Participants With Overall Response | 11.1 (1.4 to 34.7) | 29.2 (20.8 to 38.9) |
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in IMWG criteria. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component (the absolute increase must be \>=0.5 g/dL) and/or; urine M-component (the absolute increase must be \>=200 mg/24 hours) and/or; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 milligram per deciliter (mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter \[mmol/L\]) that can be attributed solely to the plasma cell proliferative disorder.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Duration of Response | NA (1.8 to NA) | 7.4 (5.5 to NA) |
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Overall Survival | 19.45 (7.72 to 26.81) | 18.60 (13.67 to 25.00) |
Clinical benefit rate defined as percentage of participants who achieved minimal response (MR) or better. MR: \>=25% but \<= 49% reduction of serum M-protein and reduction in urine M-protein by 50%-89%. If present at baseline 25% to 49% reduction in size of soft tissue plasmacytomas.
| percentage of participants | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Percentage of Participants With Clinical Benefit | 22.2 (6.4 to 47.6) | 34.0 (25.0 to 43.8) |
Time to response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better).
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Time to Response | 0.99 (0.95 to 1.02) | 0.99 (0.9 to 5.6) |
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Progression Free Survival | 4.86 (1.84 to NA) | 3.65 (2.76 to 4.63) |
Time to progression was defined as the number of days from the date of first dose of daratumumab to the date of first record of disease progression.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Time to Disease Progression | 4.86 (1.84 to NA) | 3.71 (2.79 to 5.39) |
Collected over Approximately up to 3.8 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daratumumab 8 mg/kg | — | 6/18 (33.3%) | 18/18 (100%) |
| Daratumumab 16 mg/kg | — | 33/106 (31.1%) | 105/106 (99.1%) |
| Event | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| NauseaGastrointestinal disorders | 1/18 | 0/106 |
| VomitingGastrointestinal disorders | 1/18 | 0/106 |
| General Physical Health DeteriorationGeneral disorders | 1/18 | 5/106 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/18 | 0/106 |
| Back PainMusculoskeletal and connective tissue disorders | 1/18 | 1/106 |
| Plasma Cell LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/18 | 0/106 |
| SyncopeNervous system disorders | 1/18 | 0/106 |
| Acute Kidney InjuryRenal and urinary disorders | 1/18 | 0/106 |
| Renal ImpairmentRenal and urinary disorders | 1/18 | 0/106 |
| Urinary RetentionRenal and urinary disorders | 1/18 | 0/106 |
| Event | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 9/18 | 39/106 |
| HypertensionVascular disorders | 8/18 | 12/106 |
| FatigueGeneral disorders | 6/18 | 42/106 |
| Blood Creatinine IncreasedInvestigations | 7/18 | 9/106 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/18 | 28/106 |
| ChillsGeneral disorders | 6/18 | 10/106 |
| HyponatraemiaMetabolism and nutrition disorders | 6/18 | 7/106 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/18 | 27/106 |
| NauseaGastrointestinal disorders | 4/18 | 34/106 |
| PyrexiaGeneral disorders | 5/18 | 20/106 |
All treated Analysis Set included all participants who received at least 1 dose of daratumumab.
| Age, Categorical(Participants) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 58 | 66 |
| >=65 years | 10 | 48 | 58 |
| Age, Continuous(years) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| Mean | 64.2 ± 7.72 | 62.9 ± 10 | 63.1 ± 9.68 |
| Sex: Female, Male(Participants) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| Female | 6 | 54 | 60 |
| Male | 12 | 52 | 64 |
| Region of Enrollment(Participants) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| Canada | 0 | 22 | 22 |
| Spain | 3 | 9 | 12 |
| United States | 15 | 75 | 90 |
| Stage of Disease (ISS)(Participants) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| I | 2 | 26 | 28 |
| II | 8 | 40 | 48 |
| III | 8 | 40 | 48 |
| Number of Prior Lines of Therapy(Participants) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| <= 3 Lines | 6 | 19 | 25 |
| > 3 Lines | 12 | 87 | 99 |
| Refractory to Proteasome Inhibitor (PI)/ Immunomodulatory Drug (IMiD)(Participants) | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total |
|---|---|---|---|
| Both a PI and IMiD | 15 | 101 | 116 |
| PI only | 1 | 3 | 4 |
| IMiD only | 0 | 1 | 1 |
| None | 2 | 1 | 3 |
Ran from Sep 2013 to primary completion in Jan 2015, 15 months.
Results were first posted in Feb 2017, 2 years after primary completion.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 15 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →